AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Tagrisso ...

BRITISH pharmaceutical giant AstraZeneca is investing US$3.5bn into expanding its research and development (R&D) operations ...

AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the EU for treating adult patients with ...

European Union recommends approval of AstraZeneca’s Tagrisso for patients with unresectable EGFR-mutated lung cancer ...

AstraZeneca (GB:AZN) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall Street ...

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

Despite China’s investigations into insurance fraud, allegedly illegal importation of unapproved drugs and improper ...

BMO Capital Markets analyst Etzer Darout in a note to investors said the insurance fraud probe represents a “headline risk” ...

AstraZeneca said on Wednesday its China president Leon Wang had been detained by Chinese authorities and, although it did not ...

(Alliance News) - AstraZeneca PLC on Monday said that the EU's Committee for Medicinal Products for Human Use, or CHMP, recommended its cancer drug Tagrisso as treatment for a form of lung cancer.

Tagrisso has been recommended for approval in the European Union for the treatment of adult patients with locally advanced, ...